Talawar Therapeutics plans to go public via a SPAC merger with JATT II Acquisition Corp, bringing in $285 million to advance its immunology pipeline and fund lead bispecific TALA-125 into a Phase IIb Atopic Dermatitis (AD) readout in H2 2028. The company said the cash should support a Phase I start for TALA-125 in Q1 2027 and carry development through that mid-stage milestone.

Why It Matters To Oncology

• While Talawar is focused on immunology and inflammatory disease, the financing and development strategy is relevant to oncology drug discovery teams tracking how bispecific platforms are being funded and advanced.

• TALA-125 targets IL-13 and IL-18, underscoring continued investor appetite for next-generation multispecific biology beyond cancer.

• The broader report also noted that former FDA oncology leader Richard Pazdur could rejoin the agency, a potential regulatory watchpoint for oncology developers.

The Financials

• The combined company is expected to receive $285 million in gross proceeds.

• That includes $60 million held in JATT II's trust account and a concurrent $225 million PIPE.

• The PIPE is led by Access Biotechnology, with participation from Bain Capital Life Sciences, Deep Track Capital, RA Capital Management, Janus Henderson Investors, Vianti Capital and Farallon Capital Management.

• After closing in H2 2026, the company is expected to trade on NASDAQ under the ticker TLWR.

What They're Saying

• Talawar said the proceeds are expected to fund the launch of a Phase I trial for TALA-125 in Q1 2027 and carry the company through a Phase IIb AD readout in H2 2028.

• In addition to TALA-125, Talawar has two discovery-stage programs: TALA-307 and TALA-711.

What's Next

• Investors and clinicians will watch for completion of the SPAC transaction in the second half of 2026.

• The next key clinical catalyst is initiation of the Phase I TALA-125 study in Atopic Dermatitis in the first quarter of 2027.

• For drug discovery audiences, the main milestone is whether Talawar can translate its bispecific platform into mid-stage clinical data by H2 2028.